June 25, 2014
Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine.
To get more information, click here: http://zlk.9nl.com/northwest-biotherapeutics-nwbo. There is no cost or obligation to you.
On June 19, 2014, an article featured on TheStreet.com alleged that the MD Anderson Cancer Center had “issued a stern rebuke to Northwest Biotherapeutics for making promotional, unjustified claims about results” from the ongoing drug trial.
If you own common stock in Northwest Bio and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/northwest-biotherapeutics-nwbo.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.